Delp will replace former Americas prez Stuart Kleopfer, who is retiring from the position but will continue to work with the company while Delp transitions into his position. The shift will go into effect as of January 23, the Warsaw, Ind.-based company said.
“I would like to thank Stuart for his significant contributions to the Company and congratulate Rob on his new leadership appointment. Rob is a strategic and customer-focused executive, and he is the right leader to continue to grow Zimmer Biomet’s Americas region in the future,” CEO & prez David Dvorak said in a press release.
Bonesupport said in November it appointed Patrick O’Donnell as a general manager and North American commercialization exec VP. O’Donnell will lead the company in its partnership with Zimmer-Biomet as the company looks to drive revenue growth with its Bonesupport Cerament bone void filler. O’Donnell previously held CEO positions at 3 orthopedic companies, including Histogenics and ProteoThera.
Last month, Misonix (NSDQ:MSON) said it tapped interim chief exec and former board member Stavros Vizirgianakis as its new permanent CEO. Vizirgianakis has served as interim CEO since Sept. 2, 2016, and previously held a position on the board since May 2013.
Biogen Idec (NSDQ:BIIB) said last month it named Michel Vounatsos as chief executive officer, moving from his previous position as exec vice president and chief commercial officer. Vounatsos will succeed George Scangos, who led the company since 2010 and announced he would step away from the position once a successor was found.
RTI Surgical (NSDQ:RTIX) said last month it tapped current exec VP and CFO Robert Jordheim as its interim CEO, succeeding Brian Hutchison who announced his retirement in August. Jordheim’s previous CFO responsibilities will be assumed in the interim by Wy Louw, VP and controller at RTI.